Dual Peptide Blend: Cagrilintide + Semaglutide | Appetite Control & Metabolic Research | For Research Use Only

CAGRI-SEMA is a potent research blend of two complementary peptides: Cagrilintide (an amylin analogue) and Semaglutide (a GLP-1 receptor agonist). Together, they provide a powerful synergistic effect on appetite suppression, blood glucose control, and weight loss by mimicking natural satiety hormones and enhancing insulin regulation.

This dual-action formula is gaining major interest in obesity and metabolic disorder research for its ability to achieve significant body weight reduction and cardiometabolic improvements.

🔍 Key Features

• Dual Mechanism of Action – Combines amylin and GLP-1 pathways for amplified appetite suppression

• Promotes Weight Loss – Supports sustained caloric reduction and metabolic rebalancing

• Improves Insulin Sensitivity – Enhances glucose uptake and stabilises blood sugar

• Delays Gastric Emptying – Increases satiety and reduces food cravings

• Ideal for Obesity, Diabetes & Cardiometabolic Research

⚙️ Peptide Details

Cagrilintide

• CAS Number: 2134204-59-3

• Molecular Formula: C₂₉₃H₄₅₂N₇₈O₈₅

• Molecular Weight: ~6853.2 g/mol

Semaglutide

• CAS Number: 910463-68-2

• Molecular Formula: C₁₈₇H₂₉₁N₄₅O₅₉

• Molecular Weight: ~4113.6 g/mol

• Total Dosage: 10mg per vial (common split: 5mg Cagrilintide + 5mg Semaglutide)

• Purity: ≥ 98% (HPLC Verified)

• Form: Lyophilised white/off-white powder

🧊 Storage & Handling

• Storage (lyophilised): Store at –20°C, dry and protected from light

• Reconstitution: Use bacteriostatic water or sterile saline

• Post-Reconstitution: Store at 2–8°C and use within 7–10 days

• Avoid: Repeated freeze-thaw cycles

⚠️ For Research Use Only

CAGRI-SEMA – 10mg is provided exclusively for scientific and laboratory research. It is not approved for human use, medical treatment, or veterinary application. Must be handled by qualified researchers under appropriate safety protocols.